Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 2/2021

01-02-2021 | Esophageal Cancer | Thoracic Oncology

Long-Term Outcome of Patients with Locally Advanced Clinically Unresectable Esophageal Cancer Undergoing Conversion Surgery after Induction Chemotherapy with Docetaxel Plus Cisplatin and 5-Fluorouracil

Authors: Tetsuya Abe, MD, PhD, Eiji Higaki, MD, PhD, Takahiro Hosoi, MD, Takuya Nagao, MD, Hideaki Bando, MD, PhD, Shigenori Kadowaki, MD, PhD, Kei Muro, MD, PhD, Tsutomu Tanaka, MD, PhD, Masahiro Tajika, MD, PhD, Yasumasa Niwa, MD, PhD, Yasuhiro Shimizu, MD, PhD

Published in: Annals of Surgical Oncology | Issue 2/2021

Login to get access

Abstract

Background

Although definitive chemoradiotherapy (CRT) is recommended for patients with locally advanced unresectable esophageal cancer, the outcome is unsatisfactory. We previously demonstrated the safety and efficacy of induction chemotherapy with docetaxel plus cisplatin and 5-fluorouracil (DCF) and subsequent conversion surgery (CS) for patients with locally advanced unresectable esophageal cancer. However, whether or not induction DCF chemotherapy and subsequent CS improve the long-term outcomes of patients with locally advanced unresectable esophageal cancer is unclear.

Methods

A total of 177 consecutive patients with locally advanced unresectable esophageal cancer without distant metastasis were included in this study. Of these, 55 patients received DCF induction chemotherapy, of whom 36 underwent CS. We divided these 36 patients into two groups according to clinical response, which was analyzed retrospectively.

Results

The toxicities related to DCF chemotherapy were manageable. The response rate to induction DCF chemotherapy was 67%. R0 resection was achieved in 81% of the 36 patients who underwent subsequent CS. No serious postoperative complications were observed. Histopathological CR was achieved in 17% of the 36 patients, and the 3- and 5-year survival rates after CS were 61% and 54%, respectively. The outcomes of the patients who obtained good clinical response was better than the outcomes of patients who did not.

Conclusions

Induction DCF chemotherapy and subsequent CS show acceptable toxicity and offer the chance of long-term survival in patients with locally advanced clinically unresectable esophageal cancer.
Appendix
Available only for authorised users
Literature
1.
Shinoda M, Ando N, Kato K, et al. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci. 2015;106(4):407–12.PubMedPubMedCentralCrossRef
2.
Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17(9):2915–21.PubMedCrossRef
3.
Okamura A, Hayami M, Kozuki R, et al. Salvage esophagectomy for initially unresectable locally advanced T4 esophageal squamous cell carcinoma. Esophagus. 2020;17(1):59–66.PubMedCrossRef
4.
Takeuchi M, Kawakubo H, Mayanagi S, et al. Postoperative pneumonia is associated with long-term oncologic outcomes of definitive chemoradiotherapy followed by salvage esophagectomy for esophageal cancer. J Gastrointest Surg. 2018;22(11):1881–9.PubMedCrossRef
5.
Markar S, Gronnier C, Duhamel A, et al. Salvage surgery after chemoradiotherapy in the management of esophageal cancer: Is it a viable therapeutic option? J Clin Oncol . 2015;33(33):3866–73.PubMedCrossRef
6.
Yokota T, Hatooka S, Ura T, et al. Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. Anticancer Res. 2011;31(10):3535–41.PubMed
7.
Hamai Y, Hihara J, Emi M, et al. Treatment outcomes and prognostic factors for thoracic esophageal cancer with clinical evidence of adjacent organ invasion. Anticancer Res. 2013;33(8):3495–502.PubMed
8.
Matsubara T, Ueda M, Nakajima T, et al. Can esophagectomy cure cancer of the thoracic esophagus involving the major airways? Ann Thor Surg. 1995;59(1):173–177.PubMedCrossRef
9.
Picus D, Balfe DM, Koehler RE, Roper CL, Owen JW. Computed tomography in the staging of esophageal carcinoma. Radiology. 1983;146(2):433–8.PubMedCrossRef
10.
Brierley JD, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours, 8th Edition. New York: Wiley; 2017.
11.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European J Cancer. 2009;45(2):228–47.
12.
Japanese classification of esophageal cancer, 11th Edition: part I. Esophagus. 2017;14(1):1–36.CrossRef
13.
Abe T, Hosoi T, Kawai R, et al. Perioperative enteral supplementation with glutamine, fiber, and oligosaccharide reduces early postoperative surgical stress following esophagectomy for esophageal cancer. Esophagus. 2019;16(1):63–70.PubMedCrossRef
14.
15.
Kawai R, Abe T, Uemura N, et al. Feeding catheter gastrostomy with the round ligament of the liver prevents mechanical bowel obstruction after esophagectomy. Dis Esophagus. 2017;30(6):1–8.PubMedCrossRef
16.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.PubMedPubMedCentralCrossRef
17.
Miyata H, Sugimura K, Motoori M, et al. Clinical Implications of conversion surgery after induction therapy for T4b thoracic esophageal squamous cell carcinoma. Ann Surg Oncol. 2019;26(13):4737–43.PubMedCrossRef
18.
Nakamura T OM, Ohki T, Sato T, Shirai Y, Ymamamoto M et al. Induction chemoradiotherapy followed by esophagectomy for advanced squamous cell carcinoma of the esophagus. Esophagus. 2011;8(2):89–95.CrossRef
19.
Yano M, Tsujinaka T, Shiozaki H, et al. Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy followed by surgery for T4 squamous cell carcinoma of the esophagus. J Surg Oncol. 1999;70(1):25–32.PubMedCrossRef
20.
Choi TK, Siu KF, Lam KH, Wong J. Bronchoscopy and carcinoma of the esophagus II. Carcinoma of the esophagus with tracheobronchial involvement. Am J Surg. 1984;147(6):760–2.
21.
Lehr L, Rupp N, Siewert JR. Assessment of resectability of esophageal cancer by computed tomography and magnetic resonance imaging. Surgery. 1988;103(3):344–50.PubMed
22.
Yokota T, Kato K, Hamamoto Y, et al. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer. 2016;115(11):1328–34.PubMedPubMedCentralCrossRef
23.
Yokota T, Kato K, Hamamoto Y, et al. A 3-year overall survival update from a phase 2 study of chemoselection with DCF and subsequent conversion surgery for locally advanced unresectable esophageal cancer. Ann Surg Oncol. 2020;27(2):460–7.PubMedCrossRef
24.
Terada M, Hara H, Daiko H, et al. Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE). Jpn J Clin Oncol. 2019;49(11):1055–60.PubMedCrossRef
Metadata
Title
Long-Term Outcome of Patients with Locally Advanced Clinically Unresectable Esophageal Cancer Undergoing Conversion Surgery after Induction Chemotherapy with Docetaxel Plus Cisplatin and 5-Fluorouracil
Authors
Tetsuya Abe, MD, PhD
Eiji Higaki, MD, PhD
Takahiro Hosoi, MD
Takuya Nagao, MD
Hideaki Bando, MD, PhD
Shigenori Kadowaki, MD, PhD
Kei Muro, MD, PhD
Tsutomu Tanaka, MD, PhD
Masahiro Tajika, MD, PhD
Yasumasa Niwa, MD, PhD
Yasuhiro Shimizu, MD, PhD
Publication date
01-02-2021
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 2/2021
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08865-0

Other articles of this Issue 2/2021

Annals of Surgical Oncology 2/2021 Go to the issue

Colorectal Cancer

The Landmark Series: Chemotherapy for Non-Metastatic Colon Cancer

Translational Research

Prognostic Significance of Circulating Tumor Cells with Mesenchymal Phenotypes in Patients with Gastric Cancer: A Prospective Study

Pancreatic Tumors

Relationship between Cancer Diagnosis and Complications Following Pancreatoduodenectomy for Duodenal Adenoma

Hepatobiliary Tumors

Association of RAS Mutation Location and Oncologic Outcomes After Resection of Colorectal Liver Metastases

Pancreatic Tumors

Predictors for Survival in an International Cohort of Patients Undergoing Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma

Translational Research and Biomarkers

CD36 Expression Is Associated with Cancer Aggressiveness and Energy Source in Esophageal Squamous Cell Carcinoma